Rite Aid/Revco merger: Would expand largest U.S. drug store chain to 4,500 outlets with projected annual sales of over $11 bil. Camp Hill, Penn.-based Rite Aid, will acquire Revco's 2,100 stores in a $1.8 bil. cash plus stock swap transaction announced Nov. 30. Rite Aid is offering to purchase "at least" 50.1% of Revco shares for $27.50 a share in cash and exchange Rite Aid shares for the remainder. All stores will carry the Rite Aid name and will adopt Rite Aid's internal layout. No top Revco execs are joining Rite Aid and Revco's corporate headquarters in Twinsburg, Ohio, will be closed...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The findings are consistent with some other research and likely are due to obesity patients becoming more connected to needed health care services.
Chiesi’s orphan drug Raxone has secured an English funding recommendation for the treatment of Leber's hereditary optic neuropathy, a decade after the orphan drug was approved for marketing. Chiesi told the Pink Sheet about its “long, and often challenging” road to reimbursement.
Norucholic acid and leriglitazone, for treating primary sclerosing cholangitis and cerebral adrenoleukodystrophy, respectively, are among 12 new drugs that the European Medicines Agency has started to review for potential EU marketing approval.
